An Ischemic Stroke Related to Eltrombopag Use in a Patient with Idiopathic Thrombocytopenic Purpura

Year 2016, Volume: 43 Issue: 1, - , 01.03.2016

Demet Arslan Engin Kelkitli

Abstract

Thrombopoetin receptor agonists like eltrombopag, used for Idiopathic Thrombocytopenic Purpura treatment rarely cause to the ischemic cerebrovascular disease. In this report, a patient, have been followed by ITP diagnosis for 5 years, admitted to the emergency service for right hemiparesis and aphasia. It was diagnosed as ischemic cerebrovascular disease. Etiology of patient’s cerebrovascular event was associated with eltrombopag. Because of this rare seen situation, it was argued by in the light of the literature.
Key words: Idiopathic thrombocytopenic purpura, thrombopoietin receptor agonist, eltrombopag, ischemic stroke

Keywords

İdiopatik trombositopenik purpura, Trombopoetin reseptör agonistleri, eltrombopag, İskemik inme

References

• Chen YC, Wu JS, Yang ST, et al. Stroke, angiogenesis and
• phytochemicals. Front Biosci 2012; 4:599-610.
• Bussel JB, Cheng G, Saleh MN, et al: Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. New Engl J Med 2007; 357:2237-2247.
• Park HK, Lee SH. Ischemic stroke associated with immune thrombocytopenia: lesion patterns and characteristics. Neurol Sci 2014; 35:1801-1806
• Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010; 95:1167-1175.
• Aoki T, Harada Y, Matsubara E, et al. Thrombopoietin receptor
• agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. J Clin Pharm Theraps 2012; 37:729-732.
• Norgaard M: Thrombosis in patients with primary chronic immune thrombocytopenia. Thrombosis research. 2012;130:74-75.
• Jenkins JM, Williams D, Deng Y, et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109:4739-4741.
• Catala-Lopez F, Corrales I, Martin-Serrano G, et al. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials. Med Clin 2012; 139:421-429.
• Haselboeck J, Kaider A, Pabinger I, Panzer S. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia. Thromb Haemost 2013; 109:676-683.
• Andic N, Gunduz E, Akay OM, et al. Cardiac and pulmonary
• thrombosis during multidrug treatment in an idiopathic thrombocytopenic purpura patient. Platelets 2014;25:69-70
• Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377:393-402.
• Tomiyama Y, Miyakawa Y, Okamoto S, et al: A lower starting
• dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost 2012; 10:799-806.